Biogen’s Tau-Targeting Alzheimer’s Drug Shows Clinical Signal

Biogen presented the findings at the Alzheimer’s Association International Conference, detailing how diranersen (BIIB080) successfully reduced tau levels in the brain. The drug demonstrated a clear dose-dependent reduction in cerebrospinal fluid tau and tau PET markers. However, the trial yielded a surprising outcome: the strongest clinical benefit, measured by the Clinical Dementia Rating-Sum of Boxes, occurred at the lowest dose rather than the highest.

Laura Nisenbaum, interim chief science officer at the Alzheimer’s Drug Discovery Foundation, noted that this discordance between biomarker reduction and clinical performance is the study’s most critical takeaway. Researchers are now tasked with determining whether a specific threshold of tau reduction is necessary for patient improvement or if higher concentrations of the drug introduce counterproductive effects. Despite missing the primary goal, the results underscore a shift in Alzheimer’s research toward addressing the full pathobiology of the disease. As the pipeline expands, with 75% of clinical trials now targeting pathways beyond amyloid—such as inflammation and metabolic dysfunction—this data provides a foundation for designing more precise, potentially combinatorial, treatment regimens.